[´º½º·±=À±¼±¹Î ±âÀÚ]
Ç×ü ¹ÙÀÌ¿ÀÀǾàÇ° Àü¹® Á¦¾àȸ»ç ÇÁ·¹½ºÆ¼Áö¹ÙÀÌ¿ÀÆĸ¶(´ëÇ¥ÀÌ»ç ¹Ú¼Ò¿¬)°¡ ´ç»ç Ç×ü½Å¾à PBP1510 (INN-Ulenistamab)ÀÇ ÀüÀÓ»ó µ¥ÀÌÅ͸¦ ¹ßÇ¥ÇÑ´Ù.
ȸ»ç¿¡ µû¸£¸é, À̹ø °á°ú ¹ßÇ¥´Â À¯·´Á¾¾çÇÐȸ(European Society for Medical Oncology, ESMO) ÁÖÃÖ·Î 3¿ù 7ÀϺÎÅÍ 8ÀϱîÁö °³ÃֵǴ 2022 Ç¥ÀûÇ׾Ͽä¹ý ÇÐȸ(Targeted Anticancer Therapies, TAT)¿¡¼ ÁøÇàµÈ´Ù.
À¯·´ ÃÖ´ë±Ô¸ðÀÇ ¾Ï ÇÐȸÀÎ ESMO´Â ¹Ì±¹¾ÏÇÐȸ(AACR), ¹Ì±¹ÀÓ»óÁ¾¾çÇÐȸ(ASCO)¿Í ÇÔ²² ¼¼°èÀûÀ¸·Î ±ÇÀ§ÀÖ´Â ¾Ï ÇÐȸ Áß ÇϳªÀ̸ç, À̹ø ÇÐȸ´Â ±× Áß¿¡¼µµ ‘Ç¥ÀûÇ׾Ͽä¹ý’À» ÁÖÁ¦·Î ¿Â¶óÀο¡¼ °³ÃֵƴÙ.
À̹ø ÇÐȸ¿¡¼ ÇÁ·¹½ºÆ¼Áö¹ÙÀÌ¿ÀÆĸ¶´Â °íÀ¯ÇÑ »õ Ä¡·áÇ¥ÀûÀÌÀÚ, ÃéÀå¾Ï ´ëºÎºÐ¿¡¼ ¹ß°ßµÇ´Â PAUF(Pancreatic Adenocarcinoma Up-regulated Factor) ´Ü¹éÁúÀ» ÁßÈÇÏ´Â Ç×ü½Å¾à, PBP1510ÀÇ ÀüÀÓ»ó °á°ú µ¥ÀÌÅ͸¦ Æ÷½ºÅÍ·Î ¹ßÇ¥ÇÑ´Ù.
°Ô½ÃµÈ ÀüÀÓ»ó °á°ú¿¡ µû¸£¸é, ½ÇÁ¦ ÃéÀå¾Ï°ú °¡Àå À¯»çÇÑ ¸ðµ¨ÀΠȯÀÚÀ¯·¡ ÃéÀå¾Ï¼¼Æ÷¸¦ ¸¶¿ì½ºÀÇ ÃéÀå¿¡ À̽ÄÇÏ¿© ¾ÏÀ» ¹ß»ý½ÃŲ ¸¶¿ì½º¸ðµ¨(PDX, µ¿¼ÒÀ̽Ä)½ÃÇè¿¡¼ PBP1510 Åõ¿©±ºÀº ±âÁ¸ ÈÇÐÇ×¾ÏÄ¡·áÁ¦ÀÎ Áª½ÃŸºó Åõ¿©±º ¹× ¾à¹°À» Åõ¿©ÇÏÁö ¾ÊÀº ´ëÁ¶±º¿¡ ºñÇØ À¯ÀǹÌÇÏ°Ô ³ôÀº Á¾¾ç°¨¼Ò È¿°ú¸¦ ³ªÅ¸³Â´Ù.
À±¼±¹Î ±âÀÚ news114@newsrun.co.kr
À±¼±¹Î ±âÀÚ news114@newsrun.co.kr
<ÀúÀÛ±ÇÀÚ © ´º½º·±, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>